ATE384796T1 - Modifizierter tert-promotor mit verbesserter tumorspezifität und stärke sowie diesen enthaltender rekombinanter vektor - Google Patents

Modifizierter tert-promotor mit verbesserter tumorspezifität und stärke sowie diesen enthaltender rekombinanter vektor

Info

Publication number
ATE384796T1
ATE384796T1 AT04715577T AT04715577T ATE384796T1 AT E384796 T1 ATE384796 T1 AT E384796T1 AT 04715577 T AT04715577 T AT 04715577T AT 04715577 T AT04715577 T AT 04715577T AT E384796 T1 ATE384796 T1 AT E384796T1
Authority
AT
Austria
Prior art keywords
recombinant vector
strength
vector containing
containing same
transcriptional regulatory
Prior art date
Application number
AT04715577T
Other languages
English (en)
Inventor
Chae-Ok Yun
Joo-Hang Kim
Jai-Myung Yang
Original Assignee
Ind Academic Coop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Academic Coop filed Critical Ind Academic Coop
Application granted granted Critical
Publication of ATE384796T1 publication Critical patent/ATE384796T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04715577T 2003-02-27 2004-02-27 Modifizierter tert-promotor mit verbesserter tumorspezifität und stärke sowie diesen enthaltender rekombinanter vektor ATE384796T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2003-0012364A KR100523028B1 (ko) 2003-02-27 2003-02-27 개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터

Publications (1)

Publication Number Publication Date
ATE384796T1 true ATE384796T1 (de) 2008-02-15

Family

ID=32923753

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04715577T ATE384796T1 (de) 2003-02-27 2004-02-27 Modifizierter tert-promotor mit verbesserter tumorspezifität und stärke sowie diesen enthaltender rekombinanter vektor

Country Status (7)

Country Link
US (1) US8067567B2 (de)
EP (1) EP1601772B1 (de)
JP (1) JP4327844B2 (de)
KR (1) KR100523028B1 (de)
AT (1) ATE384796T1 (de)
DE (1) DE602004011487T2 (de)
WO (1) WO2004076668A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482158B2 (en) 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
KR100747646B1 (ko) 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
KR100792183B1 (ko) 2006-05-29 2008-01-07 울산대학교 산학협력단 유전자 발현을 증가시키는 합성 ｈＴＥＲＴ 프로모터
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
KR100969171B1 (ko) * 2008-02-29 2010-07-14 연세대학교 산학협력단 종양 특이적 발현이 개선된 유전자전달체
CN103571954A (zh) * 2013-10-28 2014-02-12 深圳市第二人民医院 Tert启动子的单核苷酸多态性序列在检测泌尿系统肿瘤中的应用
EP3150706B1 (de) * 2014-05-28 2019-07-10 National University Corporation Okayama University Konditionell replizierender adenovirus zur expression eines reic-gens
AU2017375958A1 (en) 2016-12-12 2019-07-04 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
KR20190138311A (ko) 2017-04-21 2019-12-12 베이롤 칼리지 오브 메드신 종양용해성 바이러스요법 및 면역요법
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
KR102310819B1 (ko) * 2019-01-11 2021-10-12 주식회사 진캐스트 Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003104A1 (en) 1998-07-10 2000-01-20 Owen Lyell Livingston Modular walkway
DK1147181T3 (da) * 1999-02-04 2004-09-20 Geron Corp Telomerase revers transkriptase transskriptionelle regulatoriske sekvenser
CN1195056C (zh) * 2001-07-12 2005-03-30 钱其军 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法
EP1420803A1 (de) 2001-08-08 2004-05-26 Board Of Regents, The University Of Texas System Verfahren zur verstärkung der expression aus einem zellspezifischen promotor

Also Published As

Publication number Publication date
EP1601772A4 (de) 2006-08-16
DE602004011487D1 (de) 2008-03-13
KR20040077002A (ko) 2004-09-04
JP4327844B2 (ja) 2009-09-09
US8067567B2 (en) 2011-11-29
EP1601772A1 (de) 2005-12-07
US20070059287A1 (en) 2007-03-15
DE602004011487T2 (de) 2008-09-04
KR100523028B1 (ko) 2005-10-20
WO2004076668A1 (en) 2004-09-10
EP1601772B1 (de) 2008-01-23
JP2006520585A (ja) 2006-09-14

Similar Documents

Publication Publication Date Title
ATE384796T1 (de) Modifizierter tert-promotor mit verbesserter tumorspezifität und stärke sowie diesen enthaltender rekombinanter vektor
NO882341L (no) Ekspresjon av humant proapolipoprotein a-i.
NZ553701A (en) Composition comprising SC03-014 and SC03-022 antibodies against SARS-CoV
MXPA02000119A (es) Elementos mezcladores estaticos apilados.
NO20074906L (no) Polynukleotid som koder for et kimaert molekyl, vertcelle som uttrykker et kimaert molekyl og rekombinant vektor omfattende polynukleotidet
ATE266720T1 (de) Replikativer virus gesteuert von dem promotor der reversen telomerase transkriptase zur behandlung von krebs
WO1999053040A3 (de) Menschliche nukleinsäuresequenzen aus ovartumorgewebe
DE69840001D1 (de) Methoden und zusammensetzungen zur induktion einer tumorspezifischen zytotoxizität
DE60235297D1 (de) Auf lps-reagierendes chs1/beige-ähnliches anker-gen und therapeutische anwendungen davon
BR0209551A (pt) Promotor de gene especìfico de folha de café
GB0418388D0 (en) Cell therapy
TN2020000157A1 (en) Binding molecule having neutralizing activity against middle east respiratory syndrome coronavirus
DK1339853T3 (da) Isolerede luciferaser og deres anvendelse
MX2007004271A (es) Enzimas involucradas en la sintesis de triterpenos.
PE20000759A1 (es) Gen de la citocroma oxidasa de hidroquinona del tipo bd
DE59410221D1 (de) Rekombinante chladosporium herbarum allergene
ATE494375T1 (de) Frazzled nukleotidsequenzen, expressions- produkte, zusammensetzungen und verwendungen
WO2004074491A3 (en) Expression in plants of antibodies against enterotoxigenic escherichia coli
HK1082510A1 (en) Promoter to il-18bp, its preparation and use
TR200001683T2 (tr) Nükleotid sıraları, şifrelenmiş proteinler ve onların kullanımları.
WO2001027287A3 (en) Telomerase reverse transcriptase (tert) genes
AU1993201A (en) Nucleic acid sequences of hyperplasia and tumours of the thyroid
WO1995006122A3 (de) Recombinante alternaria alternata allergene
Denner-Ancona Purification and characterization of vertebrate squalene epoxidase and oxidosqualene cyclase.
Shoemaker Utility of photoaffinity labeling. I. Identification of nucleotide binding peptides within glucagon and glutamate dehydrogenase. II. Purification of a protein with aberrent nucleotide binding properties in Alzheimer's disease.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties